Literature DB >> 9266189

Iron overload and urinary lysosomal enzyme levels in beta-thalassaemia major.

H Michelakakis1, E Dimitriou, H Georgakis, F Karabatsos, C Fragodimitri, J Saraphidou, E Premetis, M Karagiorga-Lagana.   

Abstract

UNLABELLED: The urinary levels of the lysosomal enzymes N-acetyl-beta-D-glucosaminidase (NAG) (EC 3.2.1.52) and alpha-mannosidase (EC 3.2.1.24) were evaluated in patients with beta-thalassaemia major and normal control subjects. Two groups of patients with different degrees of iron overload, as judged by their serum ferritin levels, were investigated. Renal disease was not present in any of the patients. A statistically significant increase in the levels of NAG was observed in the high ferritin (> 3,000 mg/dl) group compared to the low ferritin (< 3,000 mg/dl) and the control groups. No difference was observed in the urinary alpha-mannosidase levels between the groups examined. The finding of increased NAG levels in the patients with the increased iron load suggests that kidney lysosomes are a target of iron toxicity. The different behaviour of the two lysosomal enzymes may reflect the intra- and inter-lysosomal heterogeneity in kidney.
CONCLUSION: Iron overload resulted in increased urinary levels of the lysosomal enzyme NAG which has been proposed as an early marker of kidney damage. Reduction of iron load, achieved by regular desferrioxamine infusion, resulted in normalisation of the urinary enzyme levels. Thus kidney lysosomes appear to be a target and possibly a mediator of iron toxicity in this tissue.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9266189     DOI: 10.1007/s004310050673

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  10 in total

1.  Prevalence and clinical features of cryoglobulinaemia in multitransfused beta-thalassaemia patients.

Authors:  R Perniola; C De Rinaldis; E Accogli; G Lobreglio
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

2.  GFR in Patients with β-Thalassemia Major.

Authors:  Gai Milo; Revital Feige Gross Nevo; Idit Pazgal; Anat Gafter-Gvili; Ofer Shpilberg; Uzi Gafter; Arie Erman; Pinhas Stark
Journal:  Clin J Am Soc Nephrol       Date:  2015-05-11       Impact factor: 8.237

3.  Renal tubular dysfunction in alpha-thalassemia.

Authors:  Achra Sumboonnanonda; Prida Malasit; Voravarn S Tanphaichitr; Sompong Ong-ajyooth; Siripan Petrarat; Arun Vongjirad
Journal:  Pediatr Nephrol       Date:  2003-02-26       Impact factor: 3.714

4.  Early markers of renal dysfunction in patients with beta-thalassemia major.

Authors:  Masoumeh Mohkam; Bibi Shahin Shamsian; Atoosa Gharib; Shahin Nariman; Mohammad T Arzanian
Journal:  Pediatr Nephrol       Date:  2008-06       Impact factor: 3.714

5.  Renal functions in pediatric patients with beta-thalassemia major: relation to chelation therapy: original prospective study.

Authors:  Enas A Hamed; Nagla T ElMelegy
Journal:  Ital J Pediatr       Date:  2010-05-25       Impact factor: 2.638

Review 6.  Iron metabolism in the pathogenesis of iron-induced kidney injury.

Authors:  A M F Martines; R Masereeuw; H Tjalsma; J G Hoenderop; J F M Wetzels; D W Swinkels
Journal:  Nat Rev Nephrol       Date:  2013-05-14       Impact factor: 28.314

7.  Renal tubule function in beta-thalassemia after hematopoietic stem cell transplantation.

Authors:  Achra Sumboonnanonda; Kleebsabai Sanpakit; Nuntawan Piyaphanee
Journal:  Pediatr Nephrol       Date:  2008-08-08       Impact factor: 3.714

8.  Magnetic resonance detection of kidney iron deposition in sickle cell disease: a marker of chronic hemolysis.

Authors:  Aaron Schein; Cathleen Enriquez; Thomas D Coates; John C Wood
Journal:  J Magn Reson Imaging       Date:  2008-09       Impact factor: 4.813

9.  Renal function in β-thalassemia major patients treated with two different iron-chelation regimes.

Authors:  Osama Tanous; Yossi Azulay; Raphael Halevy; Tal Dujovny; Neta Swartz; Raul Colodner; Ariel Koren; Carina Levin
Journal:  BMC Nephrol       Date:  2021-12-20       Impact factor: 2.388

10.  Impaired acylcarnitine profile in transfusion-dependent beta-thalassemia major patients in Bangladesh.

Authors:  Suprovath Kumar Sarker; Md Tarikul Islam; Golam Sarower Bhuyan; Nusrat Sultana; Mst Noorjahan Begum; Mohammad Al Mahmud-Un-Nabi; Md Abdulla Al Noman Howladar; Tashmim Farhana Dipta; A K M Muraduzzaman; Syeda Kashfi Qadri; Tahmina Shirin; Salma Sadiya; Manzoor Hussain; Waqar Ahmed Khan; Sharif Akhteruzzaman; Syed Saleheen Qadri; Firdausi Qadri; Kaiissar Mannoor
Journal:  J Adv Res       Date:  2018-04-25       Impact factor: 10.479

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.